Respiratory Medicine and Research最新文献

{"title":"The benefits of COVID lockdowns on respiratory health: What factors may have contributed to the decline in hospital admissions for cystic fibrosis?","authors":"Rebecca C. Robey , Orlagh Crozier , Arran Frame , Katrina Martin , Philip Ashcroft , Nizhat Iqbal , Peter J. Barry , Andy Jones , Shazaad Ahmad , Alexander Horsley","doi":"10.1016/j.resmer.2023.101061","DOIUrl":"10.1016/j.resmer.2023.101061","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101061"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000739/pdfft?md5=48d96c0a85f09bcc2831dfa0571f5913&pid=1-s2.0-S2590041223000739-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135411861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between persistent dyspnea and psychological distress in COVID-19 survivors. A cross-sectional evaluation at 11 months after hospitalization","authors":"Luca Bodini , Giulia Sartori , Chiara Bonetto , Michele Ranzolin , Anna Bertuetti , Francesca Miscetti , Antonio Lasalvia , Ernesto Crisafulli","doi":"10.1016/j.resmer.2023.101067","DOIUrl":"10.1016/j.resmer.2023.101067","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101067"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135715040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival comparison between the first and second waves among 265 critical COVID-19 patients admitted to the ICU: A retrospective cohort study","authors":"Nour-El-Imane Taghboulit ,&nbsp;Claire Andrejak ,&nbsp;Yazine Mahjoub ,&nbsp;Bénédicte Toublanc ,&nbsp;Isabelle Mayeux ,&nbsp;Julia Delomez ,&nbsp;Marie Mercier ,&nbsp;Pauline Leriche ,&nbsp;Julien Maizel ,&nbsp;Hervé Dupont ,&nbsp;Vincent Jounieaux ,&nbsp;Damien Basille","doi":"10.1016/j.resmer.2023.101057","DOIUrl":"10.1016/j.resmer.2023.101057","url":null,"abstract":"<div><h3>Backgroud</h3><p>Management of severe COVID-19 patients admitted to ICU considerably evolved during the first months of the pandemic. It is unclear, however, whether these changes improved long-term survival of these critically ill patients.</p></div><div><h3>Methods</h3><p>We conducted a retrospective cohort study in adults with COVID-19 pneumonia admitted to a French ICU between February 2020 and January 2021, a timeframe that covered the first two waves of the pandemic. Primary outcome was to compare long-term survival between the first and second waves. Survival predictor were identified using a Cox proportional-hazards model.</p></div><div><h3>Results</h3><p><span>We included 265 patients in the cohort: 140 (52.8 %) and 125 (47.2 %) belonging to the first and second waves, respectively. Baseline characteristics of the patients were similar between the two waves. During W2, use of early corticotherapy increased (86.4% vs. 17.8 %; </span><em>p</em> &lt;0.001), as well as high-flow oxygen therapy use (68.5% vs<em>.</em> 37.4 %; <em>p</em><span>&lt;0.001). Need for invasive mechanical ventilation decreased (49.6% vs. 72.9 %; </span><em>p</em> &lt;0.001) and ICU length of stay was shorter (11 [6–22] vs 19 [8–32]days; <em>p</em><span> = 0.008). ICU mortality was 32.8 % without significant difference between waves. Survival analysis revealed that 3 variables were independently associated with a worse long-term prognosis: a higher SAPS II score (1.05 [1.04–1.06]; </span><em>p</em>&lt;0.001), a higher age (1.05 [1.01–1.08]; <em>p</em> = 0.005) and admission during W2 (2.22 [1.15–4.28]; <em>p</em> = 0.017).</p></div><div><h3>Discussion</h3><p>Despite substantial changes on management of severe COVID-19 patients, we observed a decreased long-term survival among patients admitted during the second wave. We also noted a shorter ICU length of stay.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101057"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral cellular biomarkers in bronchiectasis","authors":"Miguel Ángel Martínez-García,&nbsp;Grace Oscullo,&nbsp;Jose Daniel Gomez-Olivas","doi":"10.1016/j.resmer.2023.101063","DOIUrl":"10.1016/j.resmer.2023.101063","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101063"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135410455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study","authors":"Ignacio Cardona-Pascual PharmD ,&nbsp;Mercedes Pallero MD, PhD ,&nbsp;David Berlana PharmD, PhD ,&nbsp;Ana Villar MD, PhD ,&nbsp;Jose Bruno Montoro-Ronsano PharmD, PhD ,&nbsp;Cristina Berastegui MD, PhD","doi":"10.1016/j.resmer.2023.101064","DOIUrl":"10.1016/j.resmer.2023.101064","url":null,"abstract":"<div><h3>Background</h3><p><span>Tocilizumab<span> is presumed to be an effective and safe treatment for severe SARS-Cov-2, but its usefulness has not been investigated yet for long-term outcomes. This study aimed to evaluate the influence of tocilizumab on mortality </span></span>in patients with SARS-CoV-2 throughout the year following discharge.</p></div><div><h3>Methods</h3><p>A retrospective observational analysis was performed on electronic medical records<span> of patients with SARS-CoV2 who were discharged from our hospital after surviving the first wave in March-April 2020. Logistic regression was used to analyse the effect of tocilizumab on mortality, as the main outcome, and propensity-score analysis to further validate their effect. Secondary outcomes were readmissions, persistent symptoms and lung function evolution. Patients were selected by matching their individual propensity for receiving therapy with tocilizumab, conditional on their demographic and clinical variables.</span></p></div><div><h3>Results</h3><p>A total of 405 patients were included in the mortality study (33.6 % were treated with tocilizumab) and 390 were included in the assessment of persistent symptoms. After propensity-score analysis, no association between tocilizumab use and 1-year overall mortality was found (HR= 2.05, 95 % CI: 0.21–19.98). No differences regarding persistent symptoms (OR= 1.01 95 %CI 0.57–1.79), nor lung function parameters (forced vital capacity: coefficient -0.16 95 %CI -0.45 to 0.14) were found throughout the year follow-up between control and tocilizumab group.</p></div><div><h3>Conclusions</h3><p>The administration of tocilizumab in patients with SARS-CoV-2 did not show any effect on long-term mortality. Identically, no association were found regarding readmissions, persistent symptoms or lung function evolution and tocilizumab administration in our cohort of patients after 1 year follow-up.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101064"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135454748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledging our reviewers","authors":"","doi":"10.1016/j.resmer.2023.101078","DOIUrl":"https://doi.org/10.1016/j.resmer.2023.101078","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101078"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000909/pdfft?md5=766337ecfc406cba71985eb1b324aa6c&pid=1-s2.0-S2590041223000909-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138570067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary adverse events of breast silicone implants and silicone injection","authors":"Eléonore Simon ,&nbsp;Laurie Pahus ,&nbsp;Pascal Chanez","doi":"10.1016/j.resmer.2023.101065","DOIUrl":"10.1016/j.resmer.2023.101065","url":null,"abstract":"<div><p><span><span><span>The incidence of breast implants and silicone injections has continuously increased since their FDA approval for use in the 1960′s. The prevalence of overall adverse events is approximately 20%. The actual incidence of pulmonary adverse events is unknown. This review focuses on the pulmonary adverse events of breast implants and silicone injections. Vascular complications are represented by acute and chronic </span>embolisation syndromes with a clinico-radiological presentation of </span>alveolar hemorrhage<span>. Inflammatory complications are numerous, including siliconoma, which is a granulomatous reaction mimicking a </span></span>mesothelioma<span><span><span>. On the other hand, there are some reports arguing a link between the development of auto-immune diseases and breast implants, such as scleroderma<span>, rheumatoid arthritis<span>, Sjögren's syndrome, and </span></span></span>dermatomyositis. Finally, for patients with asthma, breast implants may contribute to poor disease control. Cases of </span>eosinophilic granulomatosis<span><span> with polyangeitis have been described. Thus, it is of interest to decipherate mechanisms and incidence of these effects in prospective studies to better manage pulmonary diseases </span>in patients wearing breast implants in order to understand their role as culprits or bystanders. In addition, characterization of subpopulations with increased risk of adverse events is needed as we highlighted that some subpopulations seem to be at greater risk of developing them, notably asthmatics.</span></span></p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101065"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135454825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bird ownership and pulmonary outcomes apart from hypersensitivity pneumonitis in European older adults","authors":"Konstantinos Christopoulos","doi":"10.1016/j.resmer.2023.101066","DOIUrl":"10.1016/j.resmer.2023.101066","url":null,"abstract":"<div><h3>Background</h3><p>Exposure to birds has been linked with several lung pathologies and especially hypersensitivity pneumonitis, but discordant literature exist on the potential effects of this exposure on other respiratory pathologies.</p></div><div><h3>Aim</h3><p>This study aims to examine the associations between bird ownership and asthma, lung cancer, and chronic obstructive pulmonary disease (COPD) in older European adults.</p></div><div><h3>Methods</h3><p>A total of 28,109 participants from the Survey of Health, Ageing, and Retirement in Europe were employed and analyzed with multivariate logistic regressions.</p></div><div><h3>Results</h3><p>No association was found with asthma or lung cancer. Bird ownership increased the odds for COPD diagnosis (OR=1.30; 95 % CI: 1.12–1.51) and more so in males (OR=1.53; 95 % CI: 1.25–1.87) after adjustment for demographic, respiratory, lifestyle, and socioeconomic factors. Male bird owners who smoke had an even more increased risk compared to non-smokers, as did those who lived in multi-person households compared to those living alone.</p><p><em>Conclusion</em>: Bird ownership may be positively associated with COPD in older European males.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101066"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135455829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update","authors":"Isabelle Mahé ,&nbsp;Guy Meyer ,&nbsp;Philippe Girard ,&nbsp;Laurent Bertoletti ,&nbsp;Silvy Laporte ,&nbsp;Francis Couturaud ,&nbsp;Patrick Mismetti ,&nbsp;Olivier Sanchez ,&nbsp;Best Practice Guidelines for VTE Management Working Group","doi":"10.1016/j.resmer.2023.101056","DOIUrl":"10.1016/j.resmer.2023.101056","url":null,"abstract":"<div><h3>Background</h3><p>In recent years, knowledge about cancer associated thrombosis has evolved considerably.</p></div><div><h3>Methods</h3><p>Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of different scientific societies practicing in various settings. The method followed the \"Clinical Practice Guidelines\" process of the French National Authority for Health (HAS).</p></div><div><h3>Results</h3><p>After a literature review, guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease and management from the data of available clinical trials and observational studies : epidemiology, initial treatment, treatment duration, extended treatment, recurrent thrombosis, central venous catheter thrombosis, incidental thrombosis, treatment in case of thrombocytopenia.</p></div><div><h3>Conclusion</h3><p>These evidence-based guidelines are intended to guide the practical management of patients with cancer associated thrombosis</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101056"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000685/pdfft?md5=79d903e5e6ac07b2283a15dae1d75de6&pid=1-s2.0-S2590041223000685-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular profiling of patients with advanced lung adenocarcinoma diagnosed between 2015 and 2020 in French Polynesia","authors":"Merouane Messekher ,&nbsp;Hugues François ,&nbsp;Marc G. Denis ,&nbsp;Pablo Ferrer-Lopez ,&nbsp;Frédérique Bost-Bezaud ,&nbsp;Julien Mazières ,&nbsp;Éric Parrat","doi":"10.1016/j.resmer.2023.101059","DOIUrl":"10.1016/j.resmer.2023.101059","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101059"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135670549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}